Prelude Therapeutics Inc financial data

Symbol
PRLD on Nasdaq
Location
Wilmington, DE
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 10 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 307% % -60%
Debt-to-equity 61% % 153%
Return On Equity -130% % -74%
Return On Assets -81% % -34%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63,002,248 shares 14%
Entity Public Float $14,400,000 USD -78%
Weighted Average Number of Shares Outstanding, Basic 76,956,194 shares 1.5%
Weighted Average Number of Shares Outstanding, Diluted 76,956,194 shares 1.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $6,500,000 USD 117%
Research and Development Expense $94,300,000 USD -20%
General and Administrative Expense $22,406,000 USD -22%
Operating Income (Loss) $104,566,000 USD 25%
Net Income (Loss) Attributable to Parent $99,498,000 USD 22%
Earnings Per Share, Basic -1.29 USD/shares 23%
Earnings Per Share, Diluted -1.29 USD/shares 23%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $35,256,000 USD 183%
Marketable Securities, Current $67,958,000 USD -44%
Assets, Current $105,692,000 USD -22%
Property, Plant and Equipment, Net $5,113,000 USD -24%
Operating Lease, Right-of-Use Asset $27,165,000 USD -5.3%
Assets $141,315,000 USD -19%
Accounts Payable, Current $3,983,000 USD -48%
Employee-related Liabilities, Current $7,138,000 USD -21%
Accrued Liabilities, Current $12,533,000 USD -18%
Liabilities, Current $52,994,000 USD 107%
Operating Lease, Liability, Noncurrent $15,045,000 USD -1.8%
Other Liabilities, Noncurrent $2,841,000 USD -8.1%
Liabilities $72,678,000 USD 65%
Accumulated Other Comprehensive Income (Loss), Net of Tax $8,000 USD -77%
Retained Earnings (Accumulated Deficit) $683,061,000 USD -17%
Stockholders' Equity Attributable to Parent $68,637,000 USD -48%
Liabilities and Equity $141,315,000 USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $34,231,000 USD -7.7%
Net Cash Provided by (Used in) Financing Activities $160,000 USD
Net Cash Provided by (Used in) Investing Activities $62,186,000 USD 99%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $27,795,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38,491,000 USD 133%
Deferred Tax Assets, Valuation Allowance $211,904,000 USD 16%
Deferred Tax Assets, Gross $216,590,000 USD 15%
Operating Lease, Liability $17,789,000 USD -0.16%
Payments to Acquire Property, Plant, and Equipment $47,000 USD -84%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $99,525,000 USD 22%
Lessee, Operating Lease, Liability, to be Paid $38,722,000 USD -6.5%
Property, Plant and Equipment, Gross $12,042,000 USD 0.14%
Operating Lease, Liability, Current $2,744,000 USD 10%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,048,000 USD 2.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,973,000 USD 9.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $20,933,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,124,000 USD 2.5%
Deferred Tax Assets, Operating Loss Carryforwards $112,873,000 USD 38%
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,202,000 USD 2.5%
Operating Lease, Payments $620,000 USD
Depreciation, Depletion and Amortization $435,000 USD 2.1%
Deferred Tax Assets, Net of Valuation Allowance $4,686,000 USD -6.6%
Share-based Payment Arrangement, Expense $11,913,000 USD -44%